Public COA audit

Double Agonist · Tirzepatide

Audited July 29, 2026

Mostly consistent, with concerns

Several fields check out, but we found issues worth reviewing before you rely on this document.

Legitimacy
92
Confidence
93%
Panels
3/7
Purity (printed)
99.9%

Document details

Fields extracted from the certificate — not order or payment data.

Batch / lot
PR-TRZ10-B1-0626-1
Identity method
HPLC-RTM
Sample date
2026-07-06
Issue date
2026-07-24

7-panel checklist

Had data + good, had data + bad, reported without pass/fail, or missing. Missing lowers thoroughness — you decide whether that panel matters; PeptIQ’s score still factors coverage.

3 of 7 present · 3 passed · 0 failed · 0 reported · 4 missing

Missing is a thoroughness gap — not automatically bad. PeptIQ’s legitimacy score still weighs panel coverage; you can down-weight panels that don’t matter for your use case.

  • Identity

    Tested · passed · core

    Compound identity confirmed (e.g. HPLC, mass spec).

    Confirmed (Tirzepatide)

  • Purity

    Tested · passed · core

    Reported purity percentage for the analyte.

    99.90%

  • Heavy metals

    Tested · passed

    Lead, arsenic, cadmium, mercury, or similar limits.

    All Not Detected

  • Microbial

    Not on this COA

    Bioburden / microbial limits testing.

    No evidence for this panel. That lowers thoroughness — whether it matters depends on what you care about.

  • Endotoxin

    Not on this COA · core

    LAL or chromogenic endotoxin assay.

    No evidence for this panel. That lowers thoroughness — whether it matters depends on what you care about.

  • Sterility

    Not on this COA

    Sterility testing where applicable.

    No evidence for this panel. That lowers thoroughness — whether it matters depends on what you care about.

  • Residual solvent / water

    Not on this COA

    Residual solvents or water content limits.

    No evidence for this panel. That lowers thoroughness — whether it matters depends on what you care about.

How to read this

Had data · good

Panel present with a pass (or clear acceptance).

Had data · bad

Panel present with a fail — a concrete quality signal.

Had data · unclear

Value reported without an explicit pass/fail mark.

Missing

Not on this certificate. Lowers thoroughness; you decide if that panel matters for your use case. PeptIQ’s score still factors coverage.

Findings

Evidence-linked observations from this audit.

  • High HPLC purity confirmed

    99.90% purity by HPLC with clean chromatogram showing single dominant peak, consistent with high-quality research peptide

  • Identity confirmed

    Tirzepatide identity confirmed by HPLC-RTM method

  • Fentanyl screening included

    Immunoassay fentanyl screen performed with 50 ng/mL cutoff, result: Not Detected

  • Heavy metals panel complete

    ICP-MS testing for As, Cd, Pb, Hg, Cr all passed (Not Detected)

  • Complete batch identification

    COA #: COA-2026-CCSIUO, Lot: PR-TRZ10-B1-0626-1, Accession: ACC-2026-8267

  • Dates within normal range

    Sample received 2026-07-06, analyzed 2026-07-24, issued 2026-07-24 - all dates are valid and consistent

  • Lab credentials present

    ILS Laboratories, San Diego CA with ISO/IEC 17025 accreditation badge, signed by Dr. Greg Kalyuzhny (Lab Director), includes verification URL and QR code

  • Professional presentation

    Well-formatted COA with clear tables, chromatogram, product photo, and comprehensive test results. Includes client info (Padre Research) and access code for verification

  • Limited panel scope

    No microbial, endotoxin, or sterility testing reported. This is common for research-grade peptides but limits full quality assessment

PeptIQ COA reports analyze document content and publicly verifiable lab signals. They are educational and not a guarantee of product quality, legality, or safety. Always consult a qualified professional before making health decisions. We never publish purchase prices, shipping details, or uploader identity.